In conclusion, ARRDC3 upregulation with different immune cell infiltration were involved in the development of CTEPH and ARRDC3 might a potential and promising Ferroptosis-related biomarker for CTEPH treatment. Here, ARRDC3 is linked to chronic thromboembolic pulmonary hypertension.